Weiyi Fang

机构：Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University · ORCID：0000-0001-8435-7629

发表论文 101 篇 · 总被引 3221 次 · h-index 31

代表论文

• Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial (2019 · The Lancet Diabetes & Endocrinology · 被引 330)
• Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China (2020 · Journal of the American College of Cardiology · 被引 243)
• Hourly Air Pollutants and Acute Coronary Syndrome Onset in 1.29 Million Patients (2022 · Circulation · 被引 205)
• Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol (2021 · Journal of the American College of Cardiology · 被引 144)
• Non-optimum temperature increases risk and burden of acute myocardial infarction onset: A nationwide case-crossover study at hourly level in 324 Chinese cities (2022 · EClinicalMedicine · 被引 79)
• The National Chest Pain Centers Program: Monitoring and Improving Quality of Care for Patients with Acute Chest Pain in China (2021 · Cardiology Plus · 被引 54)